carbostyril has been researched along with Cancer of Prostate in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 10 (18.18) | 29.6817 |
| 2010's | 39 (70.91) | 24.3611 |
| 2020's | 5 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Aghasizadeh, M; Alavi, SJ; Bahrami, AR; Matin, MM; Moghaddam, T; Sadeghian, H | 1 |
| Anh, DT; Dung, DTM; Dung, PTP; Hai, PT; Han, SB; Huy, LD; Jun, HW; Kang, JS; Kwon, JH; Nam, NH; Park, EJ; Tung, TT; Young Ji, A | 1 |
| Ben Rhouma, S; Bibi, M; Chaker, K; Mrad Dali, K; Nouira, Y; Ouanes, Y; Rahoui, M; Sellami, A | 1 |
| Ben Aicha, I; Carignan, D; Fiset, C; Foster, W; Martin, AG; Pelchat, C; Reynaud, T; Vigneault, E | 1 |
| Lee, SY; Son, J | 1 |
| Togo, Y; Yamamoto, S | 1 |
| Baek, SW; Lee, HJ; Seo, YJ | 1 |
| Amitharaj, R; Chadwick, D; Fitzpatrick, J; Jones, P; Noreikaite, J; Pietropaolo, A; Rai, BP; Somani, BK; Vasdev, N | 1 |
| Chen, MC; Chien, WS; Day, CH; Hsu, HH; Huang, CY; Lin, TH; Padma, VV; Shen, CH; Velmurugan, BK; Wu, HC | 1 |
| Adil, MS; Alwhaibi, A; Artham, S; Somanath, PR; Verma, A | 1 |
| Hartley, AE; Heer, R; Williamson, SC | 1 |
| Chen, WC; Chien, WS; Huang, CY; Kuo, SC; Lee, SS; Lin, TH; Ting, WJ; Tsai, CH; Tsai, FJ; Wu, HC | 1 |
| Sennbro, CJ; Tiensuu, M; van de Merbel, NC; Walland, P | 1 |
| Aparicio, A; Cao, X; Chinnaiyan, AM; Corn, PG; Efstathiou, E; Iyer, MK; Kundra, V; Li Ning Tapia, EM; Logothetis, CJ; McKeehan, W; Navone, NM; Palanisamy, N; Ravoori, MK; Robinson, DR; Starbuck, MW; Tapia, EM; Troncoso, P; Vazquez, ES; Wan, X; Wang, F; Wu, YM; Yang, J; Zurita, AJ | 1 |
| Bae, SR; Choi, WS; Kim, DH; Kim, HG; Loh, YS; Paick, SH; Park, HK | 1 |
| Thoma, C | 1 |
| Bae, JH; Chang, IH; Cho, IR; Chung, H; Chung, JM; Hwang, EC; Jung, SI; Kim, TH; Kim, YH; Kwon, DD; Lee, G; Lee, SJ; Min, SK; Na, YG; Son, H | 1 |
| Abrams, SI; Adelaiye, R; Celander, M; Ciamporcero, E; Ciesielski, M; Ellis, L; Eriksson, H; Fenstermaker, R; Leanderson, T; Miles, KM; Olsson, A; Orillion, A; Pili, R; Ramakrishnan, S; Shen, L; Sundstedt, A | 1 |
| Choi, HY; Choo, SH; Han, DH; Jeon, HG; Jeon, SS; Jeong, BC; Lee, HM; Lee, KS; Lee, SW; Seo, SI; Song, W; Sung, HH | 1 |
| Loeb, S | 1 |
| Bai, J; Hua, HM; Jing, YK; Li, DH; Li, ZL; Pei, YH; Shan, DT; Sun, YT; Zhao, N | 1 |
| Chen, CH; Lai, MJ; Lee, CH; Lee, HY; Liou, JP; Liu, YM; Pan, SL; Wang, LT; Yeh, TK | 1 |
| Schaeffer, EM | 1 |
| Kabadere, S; Kus, G; Kutlu, HM; Uyar, R | 1 |
| Farach-Carson, MC; Fong, EL; Harrington, DA; Mikos, AG; Morgado, M; Navone, NM; Wan, X; Yang, J | 1 |
| Damber, JE; Hagberg Thulin, M; Magnusson, LU; Olsson, A; Plas, P; Welén, K | 1 |
| Alami, M; Barratt, G; Bruneau, A; Denis, S; Franzè, S; Legrand, FX; Lesieur, S; Messaoudi, S; Nicolas, V; Sauvage, F; Vergnaud-Gauduchon, J | 1 |
| Brower, V | 1 |
| Ho, CT; Hung, CM; Kuo, SC; Lin, YC; Liu, LC; Way, TD | 1 |
| Angelergues, A; Mejean, A; Michel, C; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y | 1 |
| Bilski, P; Rice, AB; Risek, B; Schrader, WT | 1 |
| De, SK; Dewing, A; Gaitonde, S; Krajewski, S; Pellecchia, M; Riel-Mehan, M; Robertson, G; Ronai, Z; Tcherpakov, M; Yuan, H | 1 |
| Ezell, SJ; Murugesan, S; Nadkarni, DH; Rayburn, ER; Velu, SE; Wang, F; Wang, W; Zhang, R; Zhang, Y | 1 |
| Ahlgren, G; Björk, A; Bratt, O; Damber, JE; Häggman, M; Nordle, O | 1 |
| Björk, A; Isaacs, JT; Leanderson, T; Olsson, A; Vallon-Christersson, J | 1 |
| Isaacs, JT | 1 |
| Becker, RE; Dalrymple, SL; DeWeese, TL; Isaacs, JT; Zhou, H | 1 |
| Armstrong, AJ; Assikis, VJ; Björk, A; Carducci, MA; Forsberg, G; Gingrich, JR; Häggman, M; Nordle, O; Pili, R; Stadler, WM | 1 |
| Hansson, GP; Olin, M; Sennbro, CJ; Svanström, C; Svensson, LD | 1 |
| Agarwal, N; Sonpavde, G; Sternberg, CN | 1 |
| Axelsson, B; Damber, JE; Jennbacken, K; Leanderson, T; Olsson, A; Törngren, M; Welén, K | 1 |
| Bergh, A; Björk, P; Ivars, F; Källberg, E; Leanderson, T; Liberg, D; Olsson, A; Roth, J; Vogl, T; Wikström, P | 1 |
| Cullen, IM; Fennell, JP; Flynn, RJ; Grainger, R; Manecksha, RP; McDermott, T; McEvoy, E; Nason, GJ; Thornhill, JA | 1 |
| Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Makarević, J; Mani, J; Stastny, M; Tsaur, I; Vallo, S | 1 |
| Chen, PY; Chen, YJ; Chou, LC; Huang, CY; Hwang, JM; Kuo, SC; Liu, CY; Ting, WJ; Tsai, FJ; Wu, HC | 1 |
| George, S; Pili, R | 1 |
| Björk, A; Dalrymple, SL; Garrison, JB; Isaacs, JT; Kyprianou, N; Leanderson, T; Olsson, A; Pili, R; Qian, DZ | 1 |
| Chang, W; Chapman, MS; Finn, PD; Hong, MH; López, FJ; Marschke, KB; Miner, JN; Negro-Vilar, A; Rosen, J; Schrader, W; Turner, R; van Oeveren, A; Viveros, H; Zhi, L | 1 |
| Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G | 1 |
| Becker, RE; Dalrymple, SL; Isaacs, JT | 1 |
| Autry, C; Cooper, B; Iwanicki, M; Kath, JC; Luzzio, MJ; Martin, KH; Parsons, JT; Roberts, WG; Slack-Davis, JK; Tilghman, RW; Ung, EJ | 1 |
| Mari, M | 1 |
| Audia, JE; Goode, RL; Hsiao, KC; Leibovitch, IY; McNulty, AM; Neubauer, BL; Sutkowski, DM | 1 |
| Boothman, DA; Dubyak, GR; Nieminen, AL; Pink, JJ; Tagliarino, C | 1 |
6 review(s) available for carbostyril and Cancer of Prostate
| Article | Year |
|---|---|
Prevention of infectious complications after prostate biopsy procedure.
Topics: Administration, Oral; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Biopsy; Drug Resistance, Bacterial; Gastrointestinal Microbiome; Humans; Male; Postoperative Complications; Practice Guidelines as Topic; Prostate; Prostatic Neoplasms; Quinolones; Rectum | 2017 |
Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Fosfomycin; Humans; Image-Guided Biopsy; Male; Prostatic Neoplasms; Quinolones; Ultrasonography | 2018 |
A review of tasquinimod in the treatment of advanced prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Prostatic Neoplasms; Quinolines; Quinolones | 2013 |
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hydroxyquinolines; Male; Prostatic Neoplasms; Quinolines; Quinolones | 2010 |
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cancer Vaccines; Carcinoma; Clinical Trials, Phase III as Topic; Clusterin; Dasatinib; Denosumab; Humans; Ipilimumab; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Pyridines; Pyrimidines; Quinolines; Quinolones; Radium; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thiazoles; Tissue Extracts; Treatment Outcome; Vaccines, Synthetic | 2012 |
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Immunomodulation; Male; Prostatic Neoplasms; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Tumor Microenvironment | 2013 |
3 trial(s) available for carbostyril and Cancer of Prostate
| Article | Year |
|---|---|
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Orchiectomy; Prostatic Neoplasms; Quinolines; Quinolones | 2009 |
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Calgranulin B; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prostatic Neoplasms; Quinolines; Quinolones | 2011 |
[Single dose versus 5-day course of oral prulifloxacin in antimicrobial prophylaxis for transrectal prostate biopsy].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Biopsy; Dioxolanes; Drug Administration Schedule; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Prostate; Prostatic Neoplasms; Quinolones | 2007 |
46 other study(ies) available for carbostyril and Cancer of Prostate
| Article | Year |
|---|---|
8-Geranyloxycarbostyril as a potent 15-LOX-1 inhibitor showed great anti-tumor effects against prostate cancer.
Topics: Animals; Antineoplastic Agents; Arachidonate 15-Lipoxygenase; Dose-Response Relationship, Drug; HeLa Cells; Humans; Hydroxyquinolines; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Quinolones; Xenograft Model Antitumor Assays | 2022 |
Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Hydrazines; Lung Neoplasms; Male; Molecular Docking Simulation; PC-3 Cells; Prostatic Neoplasms; Quinolones; Structure-Activity Relationship | 2022 |
Positive urine culture prior to transrectal prostate biopsy was not associated with infectious complications development.
Topics: Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatitis; Quinolones; Retrospective Studies; Urinary Tract Infections | 2022 |
Infection after prostatic transrectal fiducial marker implantation for image guided radiation therapy.
Topics: Fiducial Markers; Humans; Male; Prostatic Neoplasms; Quinolones; Radiotherapy, Image-Guided; Retrospective Studies | 2023 |
Small molecule DTDQ exerts anti-metastatic effects in DU145 human castration-resistant prostate cancer cells via modulations of ERK, JNK, p38 and c-Myc signaling pathways.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Prostatic Neoplasms; Quinolones | 2020 |
Multiple milia associated with use of the tyrosine kinase inhibitor dovitinib.
Topics: Antineoplastic Agents; Benzimidazoles; Drug Eruptions; Humans; Keratosis; Male; Middle Aged; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinolones | 2018 |
KHC-4 inhibits β-catenin expression in prostate cancer cells.
Topics: Antineoplastic Agents; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Male; Morpholines; Prostatic Neoplasms; Quinolones; Roscovitine; Signal Transduction | 2019 |
Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.
Topics: Animals; Benzodioxoles; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Forkhead Box Protein O3; Gene Silencing; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Nodal Protein; PC-3 Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Drug may slow progression and increase prostate cancer survival. A Duke study is one of three recently published investigations that reflect progress against the disease that affects millions of men.
Topics: Antineoplastic Agents; Disease Progression; Humans; Male; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis | 2014 |
Induction of apoptosis in human DU145 prostate cancer cells by KHC-4 treatment.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Humans; In Situ Nick-End Labeling; Male; Membrane Potential, Mitochondrial; Morpholines; Prostatic Neoplasms; Quinolones | 2014 |
Quantitative determination of the anti-tumor agent tasquinimod in human urine by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Female; Humans; Liquid-Liquid Extraction; Male; Prostatic Neoplasms; Quinolines; Quinolones; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neovascularization, Pathologic; Osteoblasts; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
The real practice of antibiotic prophylaxis for prostate biopsy in Korea where the prevalence of quinolone-resistant Escherichia coli is high.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Cephalosporins; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli Infections; Humans; Male; Prostate; Prostatic Neoplasms; Quinolones; Republic of Korea | 2014 |
Prostate cancer: targeting the FGFR curbs bone metastasis.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Quinolones; Receptor, Fibroblast Growth Factor, Type 1 | 2014 |
A prospective Korean multicenter study for infectious complications in patients undergoing prostate surgery: risk factors and efficacy of antibiotic prophylaxis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Diabetes Mellitus, Type 2; Drug Resistance, Bacterial; Enterococcus; Escherichia coli; Humans; Klebsiella pneumoniae; Male; Middle Aged; Odds Ratio; Postoperative Complications; Prospective Studies; Prostatic Neoplasms; Quinolones; Risk Factors; Time Factors; Transurethral Resection of Prostate; Urinalysis; Urinary Tract Infections | 2014 |
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Castration; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Drug Evaluation, Preclinical; Immune Tolerance; Immunotherapy; Male; Melanoma, Experimental; Mice, Inbred C57BL; Myeloid Cells; Neoplasm Transplantation; Prostatic Neoplasms; Quinolines; Quinolones; T-Lymphocyte Subsets | 2015 |
Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy.
Topics: Aged; Aminoglycosides; beta-Lactamases; Biopsy; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Male; Middle Aged; Prostatic Neoplasms; Prostatitis; Quinolones; Rectum; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
Editorial comment.
Topics: Biopsy; Escherichia coli; Escherichia coli Infections; Humans; Male; Prostatic Neoplasms; Prostatitis; Quinolones | 2014 |
Quinolone and indole alkaloids from the fruits of Euodia rutaecarpa and their cytotoxicity against two human cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Evodia; Fruit; HL-60 Cells; Humans; Indole Alkaloids; Male; Molecular Structure; Plant Extracts; Prostatic Neoplasms; Quinolones | 2015 |
1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Mice, Nude; Molecular Structure; Prostatic Neoplasms; Quinolones; Xenograft Model Antitumor Assays | 2015 |
Re: Incidence and Management of Extended-Spectrum Beta-Lactamase and Quinolone-Resistant Escherichia coli Infections after Prostate Biopsy.
Topics: Biopsy; Escherichia coli; Escherichia coli Infections; Humans; Male; Prostatic Neoplasms; Prostatitis; Quinolones | 2015 |
Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Ceramidases; Humans; Male; Microscopy, Confocal; Microscopy, Electron, Transmission; Prostate; Prostatic Neoplasms; Quinolones | 2015 |
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
Topics: Adenocarcinoma; Animals; Benzimidazoles; Bone Neoplasms; Cell Communication; Cell Culture Techniques; Cell Line; Coculture Techniques; Gene Expression Profiling; Heterografts; Humans; Hydrogels; In Vitro Techniques; Male; Mice; Neoplasm Proteins; Osteoblasts; Peptides; Prostatic Neoplasms; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; RNA Interference; RNA, Small Interfering; Stromal Cells; Tissue Engineering; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cytokines; Heterografts; Humans; Immune Tolerance; Inflammation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Osteoblasts; Osteogenesis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Tibia; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Movement; Doxorubicin; Drug Delivery Systems; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Liposomes; Male; Phospholipids; Prostatic Neoplasms; Quinolones | 2016 |
Tasquinimod treatment for prostate cancer.
Topics: Antineoplastic Agents, Immunological; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Male; Prostatic Neoplasms; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
Topics: Animals; Antimitotic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Microtubules; Polymerization; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinolones; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tubulin; Up-Regulation | 2016 |
Topics: Antibodies, Monoclonal; Cancer Vaccines; Cell Cycle Checkpoints; Humans; Immunomodulation; Immunotherapy; Ipilimumab; Lenalidomide; Male; Nivolumab; Programmed Cell Death 1 Receptor; Prostatic Neoplasms; Quinolines; Quinolones; Thalidomide; Tissue Extracts; Vaccines, Synthetic | 2016 |
Androgen receptor-mediated apoptosis is regulated by photoactivatable androgen receptor ligands.
Topics: Active Transport, Cell Nucleus; Androgen Receptor Antagonists; Apoptosis; Base Sequence; Cell Line, Tumor; Dihydrotestosterone; DNA Damage; Humans; Ligands; Male; Metribolone; Models, Biological; Oxidative Stress; Photobiology; Photochemotherapy; Photosensitizing Agents; Prostatic Neoplasms; Pyridines; Quinolones; Receptors, Androgen; Recombinant Proteins; RNA, Small Interfering; Transfection | 2008 |
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzimidazoles; Cell Death; Cell Line, Tumor; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Male; Melanoma; Mice; Mice, Nude; Models, Molecular; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinolones; Remission Induction; Xenograft Model Antitumor Assays | 2009 |
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Quinolones; Receptors, Androgen | 2010 |
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Quinolines; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondin 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinolines; Quinolones; Radiation-Sensitizing Agents; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry.
Topics: Chromatography, Liquid; Drug Stability; Humans; Male; Prostatic Neoplasms; Quinolines; Quinolones; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Down-Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Nude; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Quinolines; Quinolones; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
S100A9 interaction with TLR4 promotes tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Calgranulin B; CD11b Antigen; Cell Proliferation; Down-Regulation; Humans; Lymphoma; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Binding; Quinolines; Quinolones; Spleen; Toll-Like Receptor 4; Transforming Growth Factor beta | 2012 |
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fever; Humans; Male; Meropenem; Middle Aged; Ofloxacin; Prospective Studies; Prostate; Prostatic Neoplasms; Quinolones; Sepsis; Thienamycins; Treatment Outcome | 2012 |
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Topics: Acetylation; Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Male; Panobinostat; Prostatic Neoplasms; Quinolones; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2013 |
KHC-4 anti-cancer effects on human PC3 prostate cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Dose-Response Relationship, Drug; Flavonoids; Humans; Male; Matrix Metalloproteinase 2; Morpholines; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinolones | 2012 |
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Cell Growth Processes; Cell Line, Tumor; Dogs; Humans; Hydroxyquinolines; Male; Mice; Neovascularization, Pathologic; Prostatic Neoplasms; Quinolines; Quinolones; Rats; Xenograft Model Antitumor Assays | 2006 |
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.
Topics: Administration, Oral; Aminoquinolines; Animals; Antineoplastic Agents, Hormonal; Biomechanical Phenomena; Cell Line, Tumor; Copulation; Fluoxymesterone; Humans; Lumbar Vertebrae; Male; Muscle, Skeletal; Orchiectomy; Osteosarcoma; Prostate; Prostatic Neoplasms; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Spodoptera | 2007 |
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Cellular characterization of a novel focal adhesion kinase inhibitor.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Dose-Response Relationship, Drug; Female; Focal Adhesion Protein-Tyrosine Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinolones; Signal Transduction; Sulfones | 2007 |
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.
Topics: Adenocarcinoma; Cell Division; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Oxidoreductases; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolones; Tumor Cells, Cultured | 1996 |
Calcium is a key signaling molecule in beta-lapachone-mediated cell death.
Topics: 4-Nitroquinoline-1-oxide; Adenosine Triphosphate; Apoptosis; Blotting, Western; Breast Neoplasms; Calcium; Cell Death; Cell Division; Chelating Agents; Cytosol; DNA Fragmentation; Dose-Response Relationship, Drug; Egtazic Acid; Endoplasmic Reticulum; Female; Flow Cytometry; Humans; In Situ Nick-End Labeling; Male; Membrane Potentials; Microscopy, Confocal; Mitochondria; Models, Biological; Naphthoquinones; Prostatic Neoplasms; Quinolones; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2001 |